Sanofi: Lung Neoplasms trials
The registry lists 23 Lung Neoplasms studies with Sanofi as lead sponsor. 1 are open to participants now and 5 have results posted.
Phase 1 7Phase 2 9Phase 3 8No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS MutationsRecruitingNCT07629960Phase 1/2
- Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus GemcitabineCompletedNCT00753714Phase 2Results posted
- A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung CancerCompletedNCT00532155Phase 3Results posted
- Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC PatientsCompletedNCT00418886Phase 3Results posted
- ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung CancerCompletedNCT00312377Phase 3Results posted
- Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung AdenocarcinomaCompletedNCT00284141Phase 2Results posted
- (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsTerminatedNCT05241873Phase 1
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLCTerminatedNCT05153408Phase 1
- Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid TumorsTerminatedNCT05013554Phase 1
- (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCTerminatedNCT04862780Phase 1
- External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLCStatus unknownNCT04697446
- Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLCCompletedNCT03326752Phase 1
- Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung CancerCompletedNCT01266512Phase 2
- Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)CompletedNCT01082549Phase 3
- Tax First-line Chemotherapy With Different Doses and Then Maintenance TherapyCompletedNCT01038661Phase 3
- Weekly Docetaxel and Four Weekly Carboplatin in Non-small Cell Lung Cancer Carbo-TaxCompletedNCT00826852Phase 2
- ZD6474(Vandetanib) + Alimta Combo StudyCompletedNCT00506051Phase 1
- Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + EtoposideCompletedNCT00290953Phase 2/3
- Docetaxel in Non Small Cell Lung Cancer (NSCLC)CompletedNCT00258739Phase 2
- Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00174772Phase 2
- GILT Docetaxel - Non-Small Cell Lung CancerCompletedNCT00174629Phase 3
- ZD6474 in Treating Patients With Small Cell Lung CancerCompletedNCT00066313Phase 2
- Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00017459Phase 3